NCT03169894View on ClinicalTrials.gov

Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis

PHASE1TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 14, 2017

Primary Completion Date

September 14, 2021

Study Completion Date

October 12, 2021

Conditions
Crohn DiseaseUlcerative Colitis
Interventions
DRUG

MDGN-002

MDGN-002 is a fully human IgG4 monoclonal antibody specific to human LIGHT.

Trial Locations (13)

19104

Penn Presbyterian Medical Center, Philadelphia

The Center for Pediatric Inflammatory Bowel Disease, Children's Hospital of Philadelphia, Philadelphia

30322

Egleston Hospital, Atlanta

33016

Sweet Hope Research Specialty, Inc., Hialeah

34653

Advanced Research Institute, Inc., New Port Richey

37232

Vanderbilt University Medical Center, Nashville

40202

University of Louisville, Louisville

45267

University of Cincinnati, Cincinnati

66160

University of Kansas Medical Center, Kansas City

77030

The University of Texas Health Science Center at Houston, Houston

78212

Clinical Associates in Research Therapeutics of America, LLC, San Antonio

84124

Care Access Research, Salt Lake City

08900

Hassman Research Institute, Berlin

Sponsors
All Listed Sponsors
lead

Avalo Therapeutics, Inc.

INDUSTRY

NCT03169894 - Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis | Biotech Hunter | Biotech Hunter